StockNews.AI
TMO
StockNews.AI
34 days

Thermo Fisher Scientific and Sanofi Expand Strategic Partnership to Enable Additional U.S. Drug Product Manufacturing

1. Thermo Fisher acquires Sanofi's Ridgefield site in New Jersey. 2. Acquisition boosts U.S. drug manufacturing capacity for pharma and biotech. 3. Sanofi's facility will enhance production of essential medicines. 4. Completion of deal expected in H2 2025, pending conditions. 5. Partnership with Sanofi aims to maintain supply chain stability.

8m saved
Insight
Article

FAQ

Why Bullish?

The acquisition enhances TMO's manufacturing capabilities, positioning it favorably against competition. Similar acquisitions have historically led to increased market share and revenue growth in the biotech sector.

How important is it?

The acquisition provides significant growth opportunities, reflecting Thermo Fisher's commitment to addressing market demand. This strategic move is likely to enhance investor confidence in TMO's future performance.

Why Long Term?

The benefits from this acquisition will manifest longer-term as manufacturing capabilities improve. Historical trends indicate that integration and expanded operations take time to reach full potential.

Related Companies

SNYPFEBMY
-Thermo Fisher to Acquire Sanofi’s Steriles Manufacturing Site in Ridgefield, New Jersey to Produce Critical Medicines for SanofiEnables Additional U.S. Manufacturing Capacity to Serve Increased Demand for Pharma/Biotech Customers WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. Under the agreement, Thermo Fisher will acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey and will continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will expand use of the site to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity. The Ridgefield site is a state-of-the-art sterile fill-finish and packaging facility with a world-class team of more than 200 employees who will join Thermo Fisher following the completion of the transaction. “Sanofi’s Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “We will also expand and further strengthen our long-standing partnership with Sanofi, while investing to bring additional capacity and enhanced capabilities at this site. We look forward to welcoming all Ridgefield employees to Thermo Fisher later this year.” Brendan O’Callaghan, global head of manufacturing & supply, Sanofi, added, "This expansion of our long-term partnership with Thermo Fisher will help ensure a continued supply of high-quality Sanofi products, maintaining our commitment to American manufacturing and supporting our customers and patients in the U.S., while enabling the future development and growth of the site." Thermo Fisher operates a leading global sterile fill-finish manufacturing network, which currently includes U.S. sites in Greenville, North Carolina and Plainville, Massachusetts. These sites are integral to the company’s Accelerator™ Drug Development 360° CDMO and CRO solutions, transforming the pharmaceutical value chain for emerging biotech and biopharma companies to speed life-changing medicines to patients. The transaction is expected to be completed in the second half of 2025, subject to customary closing conditions. Upon completion of the transaction, Sanofi’s Ridgefield facility will become part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com. Forward-Looking Statements This communication contains forward-looking statements that involve a number of risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements, but other statements that are not historical facts may also be deemed to be forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: any natural disaster, public health crisis or other catastrophic event; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, including the proposed acquisition of Sanofi’s Ridgefield, NJ site, may not materialize as expected; the proposed acquisition of Sanofi’s Ridgefield, NJ site not being timely completed, if completed at all; regulatory approvals required for the transaction not being timely obtained, if obtained at all, or being obtained subject to conditions; Sanofi’s Ridgefield, NJ site business experiencing disruptions as a result of the acquisition or due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with employees, customers, other business partners or governmental entities; difficulty retaining key employees; the outcome of any legal proceedings related to the proposed acquisition of Sanofi’s Ridgefield, NJ site; and the parties being unable to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in Thermo Fisher's most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q, which are on file with the U.S. Securities and Exchange Commission ("SEC") and available in the "Investors" section of Thermo Fisher's website, ir.thermofisher.com, under the heading "SEC Filings". While Thermo Fisher may elect to update forward-looking statements at some point in the future, Thermo Fisher specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing Thermo Fisher’s views as of any date subsequent to today. More News From Thermo Fisher Scientific Inc.

Related News